An Open-Label Multicenter Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors | NYU Langone Health

Go Back to All Clinical Trials

An Open-Label Multicenter Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Melanoma
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) At least one measurable and injectable (including use of image-guided injection) tumor of = 1 cm in longest diameter (or shortest diameter for lymph nodes) 2) Females of childbearing potential must have negative beta-human chorionic gonadotropin [ß-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG within 72 hours prior to dosing

You may not be eligible for this study if the following are true:

1) Prior treatment with an oncolytic therapy 2) Has a known history of Hepatitis B or known active Hepatitis C virus or human immunodeficiency virus (HIV) infection. 3) Had systemic infection requiring intravenous (IV) antibiotics or other serious infection within 14 days prior to dosing.